Epileptic spasms - 175 years on: Trying to teach an old dog new tricks by Wilmshurst, JM et al.
Epileptic spasms – 175 years on: Trying to teach an old dog new tricks. 
Jo M Wilmshurst,1 Roland Ibekwe,1 Finbar JK O’Callaghan2 
1. Department of Paediatric Neurology, Department of Paediatrics and Child Health, Red Cross War 
Memorial Children’s Hospital, University of Cape Town, South Africa 
2. Section of Clinical Neurosciences, UCL Institute of Child Health, London, United Kingdom  
Corresponding author: Prof Jo M Wilmshurst, Department of Paediatric Neurology, Department of 
Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, University of Cape Town, 
South Africa 
e-mail: jo.wilmshurst@uct.ac.za 
tel: +27 21 658 5370 
fax: +27 21 6589 1287 
Abstract: 205 
Main text: 4378 
 
  
Abstract 
Infantile spasms, first described by Dr West in 1841, has undergone extensive investigation to 
understand the pathogenesis, aetiologies, optimal intervention and most likely prognosis for the 
affected child. The terminology has recently evolved such that the preferred term for the  condition is 
now “epileptic spasms” in recognition of the fact that cases can present outside infancy. The 
aetiologies are diverse and can be structural, genetic, metabolic  or acquired. Increasing numbers of 
presumed causative genetic mutations are now being identified. The condition is an epileptic 
encephalopathy such that without adequate control of the clinical seizures and correction of the 
abnormal EEG, ongoing neurological damage occurs. In some cases neuroregression is inevitable 
despite intervention. First-line treatments are either hormonal therapies, adrenocortcotrophic hormone 
or prednisolone, or vigabatrin. In the sub-group of patients with tuberous sclerosis complex, vigabatrin 
is the preferred treatment. High dose prednisolone may be a more viable option in resource limited 
settings. Recent research has suggested that combining hormonal therapies with vigabatrin will result 
in more patients achieving spasm cessation. Despite extensive study, the pathogenic mechanisms 
remain an area of debate and in need of further exploration. The enigma, however, may be explained 
as the role of resting state and dysfunctional brain networks are elucidated further. 
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The history of Infantile spasms 
Infantile spasms (IS) were first described by Dr West in 1841 when he wrote a letter to the Lancet 
about his own child’s clinical events. His son was healthy until 4 months of age when Dr West noticed 
that he had “slight bobbings of the head forward” which increased in frequency and intensity with time. 
He reported that whilst he was a “fine grown child” he lacked “intellectual vivacity” and “power of 
moving his limbs, of a child of his age”.(West, 1841)Over 100 years later, in 1954, Gibbs et al 
published their description on hypsarrhythmia in Pediatrics.(Gibbs et al., 1954). This 
electroencephalographic finding in IS was described as chaotic and disorganized background activity 
with asynchronized large amplitude slow waves mixed with single focal, multifocal spikesand slow 
wave followed by attenuation. In 1958, reported that adrenocorticotrophic hormone (ACTH) controlled 
the spasms in a number of cases.(SOREL and DUSAUCY-BAULOYE, 1958) Previously there were 
no known effective treatments for the condition. After this report numerous other studies have 
confirmed the efficacy of ACTH, corticosteroids and vigabatrin. 
Since then the semiology of infantile spasms, both clinically and electrically, has been extensively 
reviewed and the term West Syndrome established, consisting of the triad of spasms, intellectual 
disability and hypsarrythmia.  
Infancy is the highest risk period for epileptic seizures and epileptic spasms are the most prevalent 
infantile epilepsy type.(Wilmshurst et al., 2015) The morbidity from this type of epilepsy is often 
significant.  
As the condition was studied more it became evident that cortical malformations and genetic 
disorders were important causes of IS.  
A large single centre study of 150 infants with infantile spasms, assessed their long term 
outcome.(Jeavons et al., 1973) The subsequent prognosis of this group was that 22% died,16% 
attended normal school and the remainder required school learning support or day-care, with 34% 
severely affected. Fifty-five percent went on to develop other seizure types and 47% had abnormal 
neurological signs. Overall they illustrated the legacy of neurodisability associated with the majority of 
children who had infantile spasms.(Jeavons et al., 1973) This was further supported by the findings of 
Riikonen et al in the epidemiological study of patients with IS in Finland.(Riikonen, 1982) Poor 
prognosis related to early onset, long duration of spasms and presence of developmental delay at 
onset. But the infants with “cryptogenic aetiology” had a better prognosis.(Jeavons et al., 1973) 
(Riikonen, 1982)  
Definitions 
The West Delphi study group, following input from 31 clinicians in 15 countries, devised criteria for 
diagnosing infantile spasms based on clinical signs.(Lux and Osborne, 2004)The group concluded 
that the primary clinical outcome, namely cessation of spasms, should be defined by the absence of 
witnessed spasms from within 14 days of commencement of treatment, and 28 consecutive days,or 
more, from the last witnessed spasm. Primary electroclinical outcome was defined by cessation of 
spasms with resolution of hypsarrhythmia. The group defined West syndrome as a subset of the 
syndrome of infantile spasms. They supported the idea that an infantile spasms single-spasm variant 
should be recognized. The report provides a standard for reporting modifying and atypical features of 
hypsarrhythmia. It also suggests a minimal set of baseline characteristics and outcomes that should 
be reported in trials of patients with infantile spasms, and suggests a standard definition of relapse. 
The group were unable to reach consensus on a definition of hypsarrhythmia. 
Clearly access to electroencephalography (EEG) is important in the diagnosis and management of 
infantile spasms. But access to EEG in resource limited settings is a major challenge, as in most 
settings the tool is not available, or is limited to psychiatric or adult neurology services.(Wilmshurst et 
al., 2013) Pre-symptomatic monitoring with regular EEGs is recommended in high-risk populations 
such as infants with TSC.(Curatolo et al., 2012) Also for assessment of subtle spasms, prolonged 
EEG monitoring has been supported with video-EEG studies between 8-24 hours in 
duration.(Wilmshurst et al., 2015) These logical recommendations are also not viable in most 
resource limited settings. 
The condition of late-onset infantile spasms is an accepted entity, to the extent that the preferred term 
is no longer infantile spasms but now referred to as late-onset epileptic spasms.(Ronzano et al., 2015; 
Ishikawa et al., 2014) This condition is often associated with focal cortical dysplasia type 
1.(Metsähonkala et al., 2015) Patients may have severe mental impairment but seizures can be 
remedial to surgical interventions. These late-onset epileptic spasms (ES) are distinct from West 
syndrome and Lennox-Gastaut syndrome. In a study of 8 symptomatic patients with late-onset 
ES(Ishikawa et al., 2014) all patients had neurological deterioration in addition to multiple seizure 
types, which were intractable in seven. Interictal EEG showed no typical hypsarrhythmia. The 
predominant tonic seizures were ES, spasms followed by tonic seizures (SFT), and tonic seizures. 
The clinical characteristics were reported to be consistent with infantile epileptic encephalopathy with 
late-onset spasms in those infants with core seizure types of ES, SFT, and tonic seizures, ES beyond 
the age of 1 year, and neurological deterioration.  
It is through the recognition that infantile spasms are not restricted to the infantile period that the 
terminology has moved away from this to re-terming the condition “epileptic spasms” (ES).(Berg et al., 
2010) 
Epidemiology 
Epileptic spasm is an age related disorder. It is the most common epileptic syndrome in infancy. The 
incidence of IS has been estimated to range 2-5/10,000 newborne. Studies from high income 
countries showed wide range incidence rate (0.05 -0.6/ 1000 liveborne)  higher reported incidence 
were reported from the higher geographic latitudes; Sweden, Finland and Denmark and lowest 
incidence in United States of America, Britain and Korea. It is not clear if this difference were due to 
environmental factors or specific genetic predisposition. The age specific prevalence is around 1-
2/10000 children by age of 10 years. Like incidence the highest prevalence values also corresponds 
to high geographical latitude.(Cowan and Hudson, 1991; Riikonen, 2001; Pavone et al., 2014)There 
are scant report from sub-Saharan Africa on the incidence or prevalence of ES. In the review of the 
epidemiology of epilepsy in resource limited countries Senanayaka and Roman did not include 
epileptic spasm among the seizure types reviewed,(Senanayake and Román, 1993) while in a survey 
of childhood epilepsy in rural Uganda, though none of the 440 children reviewed then had ES, 7 of 
them had previous history suggestive of ES.(Duggan, 2010)  
The age of onset is reported to vary from the first week of life up to 3 years. The peak is between 4 
and 7 months, age of onset is within one year in 94% of cases. Almost all cases occur within 3 years 
of age.  However, rare cases of epileptic spasm with onset at up to 14 years of age are reported, 
hence the new preferred term of epileptic spasm which was first suggested in the 1991 workshop of 
the ILAE commission on paediatric epilepsy.(International and Epilepsy., 1992)  
Whilst studies suggest a slight male predominance in the prevalence of ES in the average ratio of 6:4, 
this finding is not consistent. The reason for this differnces is not clear, Brna et al suggested that the 
observed male predominance in some studies simply reflects the predominance in males in the 
referring population.(Brna et al., 2001) An alternate explanation is the increased complication rate in 
predisposing conditions such as neonatal hypoglycaemia and HIE reported to occur in male 
infants.(Tundidor et al., 2012) 
 
Aetiologies 
A study of 269 infants with ES in a national childhood encephalopathy study, found that 34% had 
antecedent factors which may have caused the spasms, the commonest of these were perinatal 
hypoxia in 38 cases and TSC in 16 cases.(Bellman et al., 1983) This case control analysis showed no 
significant association between ES and pertussis immunisation in the 28 days before onset. There 
was some clustering of cases immunised with either diphtheria, tetanus and pertussis (DTP) or DT 
vaccines in the 7 days before onset.This study was important to emphasise and support that 
vaccinations did not cause ES but could trigger their onset in infants in whom the disorder was 
predestined to develop.  
A further study of 207 infants with epileptic spasms found that, 127 (61%) had a proven aetiology, 68 
(33%) had no identified aetiology, and 12 (6%) were not fully investigated.(Osborne et al., 2010). 
Aetiologies were prenatal in 63, perinatal in 38, postnatal in 8, and 18 had other causes. The most 
common aetiologies were: hypoxic-ischemic encephalopathy (HIE) n=21 (10%), chromosomal n=16 
(8%), malformations n=16 (8%), stroke n=16 (8%), tuberous sclerosis complex (TSC) n=15 (7%), and 
periventricular leukomalacia or hemorrhage n=11 (5%). The remaining 32 aetiologies were all 
individually uncommon.  
The National Infantile Spasms Consortium in North America prospectively evaluated the aetiology of 
new-onset epileptic spasms and evaluated the yield of genetic and metabolic investigations in those 
without obvious cause after initial clinical evaluation and magnetic resonance imaging (MRI).(Wirrell 
et al., 2015)Twenty-one United States paediatric epilepsy centers prospectively enrolled infants with 
newly diagnosed West syndrome in a central database. A total of 251 infants were enrolled (53% 
male). A cause was identified in 161 (64.4%) of 250 cases (genetic,14.4%; genetic-structural, 10.0%; 
structural-congenital, 10.8%; structural-acquired, 22.4%; metabolic, 4.8%; and infectious, 2.0%). An 
obvious cause was found after initial clinical assessment (history and physical examination) and/or 
MRI in 138 of 161, whereas further genetic and metabolic studies were revealing in another 23 cases. 
Of 112 subjects without an obvious cause after initial evaluation and MRI, 81 (72.3%) had undergone 
genetic testing, which showed a causal abnormality in 23.5% and a variant of unknown significance in 
14.8%. Although metabolic studies were done in the majority, these revealed an aetiology in only five 
cases (4.5%). The group concluded that the clinical evaluation and MRI provided a specific diagnosis 
in 55% of children presenting with West syndrome. They recommended a cost-effective workup for 
those without obvious cause, after initial clinical evaluation and MRI,that should include an array 
comparative genomic hybridization (aCGH) followed by an epilepsy gene panel if the microarray is not 
definitive, as well as serum lactate, serum amino acids, and urine organic acids. 
Genetics causes are increasingly recognised as a cause of epileptic spasms. Genetic causes can 
either be disorders of genomic imbalance (e.g.Down’s syndrome, Palister-Killian syndrome, Williams 
syndrome or Miller-Dieker syndrome) or single gene disorders such as mutations in CDKL5, STXBP1, 
or ARX. Recent discoveries of responsible gene mutations, such as in GRIN2B that codes for the 
NR2B sub-unit of the N-methyl-D-aspartate (NMDA) receptor and results in a gain of function , raise 
the possibilitor of novel treatments that may be directed at the molecular pathology e.g NMDA 
receptor antagonists.(Lemke et al., 2014) A recent study of 73 infants with ES and no clear aetiology 
underwent array-CGH and molecular analysis of 5 genes (CDKL5, STXBP1, KCNQ2, GRIN2A and 
MAGI2).(Boutry-Kryza et al., 2015) A disease-causing mutation or CNV (Copy Number Variation) was 
identified in 15% of the patients. Which included 6 point mutations found in CDKL5 (n = 3) and 
STXBP1 (n = 3), 3 microdeletions (10 Mb in 2q24.3, 3.2 Mb in 5q14.3 including the region upstream 
to MEF2C, and 256 kb in 9q34 disrupting EHMT1), and 2 microduplications (671 kb in 2q24.3 
encompassing SCN2A, and 11.93 Mb in Xq28). In addition, 3 CNVs as potential risk factors, including 
one 16p12.1 deletion, one intronic deletion of the NEDD4 gene, and one intronic deletion of CALN1 
gene. 
Metabolic aetiologies are rare but also recognised. Pyridoxine dependency, biotinidase deficiency, 
PEHO syndrome, mitochondrial disorders, molybdenum co-factor deficiency and non-ketotic 
hyperglycinaemia have all been described.(Alrifai et al., 2014)  
Pathogenesis 
The underlying pathogenesis of ES is not fully understood. The condition is proposed to be a 
derangement of a network, or a system epilepsy. The mechanism for the associated encephalopathy 
is still not fully elucidated. It is hypothesised that the encephalopathy is a reflection of the background 
slowing and disruption in the normal brain rhythms due to a disturbance in brain networks. The infant 
is especially vulnerable to the development of epileptic spasms based on their stage of brain 
maturation and the time window that this places them in. Hence a wide range of aetiologies have the 
capacity of leading to the same outcome, namely ES and often West syndrome, they have the 
equivalent mechanism of flipping a switch (which may have been predestined in a vulnerable child or 
directly operational in instigating the ripple effect of damage). (Pellock et al., 2010) A common 
mechanism involved in the diverse cases of ES is proposed to be due to brainstem 
pathology.(Hrachovy and Frost, 1989) An infant with hydrancephaly was able to generate ES which 
was clinically identical to that seen in infants with intact nervous systems and supported that the 
brainstem is able to generate spasms.(Neville, 1972) Further supporting data was evident from other 
studies assessing MRI and evoked potential results, and when reviewing the progress of neonates 
who suffered hypoxic-ischaemic injuries to their subcortical and brainstem regions and subsequently 
developed ES. (Miyazaki et al., 1993; Gano et al., 2013) Further concepts arose that spasms could be 
triggered by an interaction between the cortical grey and subcortical structures. Once activated the 
subcortical, brainstem or both could become generators of epileptic spasms. (Chugani et al., 1990; 
Guggenheim et al., 2008) These findings support the idea that the pathogenesis is more complex and 
more likely related to widely disrupted networks at a particular stage of development and that this 
process is implicit in the associated encephalopathy. The encephalopathy precedes the development 
of the spasms. (Philippi et al., 2008) The EEG background pattern for children with ES and the other 
epileptic encephalopathies is typically extremely disrupted, independent of the ictal events, 
electrodecrements and periods of discontinuity which occur. (Nordli, 2014) Extending on these 
findings, the disruption in the resting state networks of the brain by chaotic brain activity could be 
responsible for the global cognitive dysfunction seen in children with epileptic encephalopathies, 
especially those with ES.(Nordli, 2013) 
Clinical Manifestation 
Semiology 
Epileptic Spasms are brief and abrupt contractions followed by less intense and sustained tonic phase 
lasting up to 1 -2 seconds which involves the muscles of the neck, trunk, upper and lower limbs. They 
are more prolonged than a myoclonic jerk but less sustained than a tonic seizure. The spasms may 
be flexor, extensor or mixed. The flexure spasms is the most common, there is however wide 
individual variability in both the intensity and type of jerks.(Pavone et al., 2014) The spasm could be 
symmetrical or asymmetrical, focal, multifocal or generalized. Children with underlying cortical 
damage may have pre-existing focal neurological signs e.g. hemiparesis that inevitably mean the 
spasms will not be symmetrical. Infact on account of the uncertainty in the true characteristics of ES, 
in the new ILAE classification of epileptic seizures ES is not classified either as focal or 
generalized.(Berg et al., 2010)The clinical significance of  subtle spasm with features such as 
yawning, gasping, isolated eye movement and transient focal motor activities which has been 
reported is unknown but they occur in the context of classical EEG pattern of IS – hypsarrythmia.(Lux 
AL & Osborne JP (2004) 
Clinical phenomena that may be associated with the motor spasm before, during or after the attack 
include cyanosis, pallor, eye deviation and or change in respiratory pattern. Cry or scream may 
precede or follow the ictal phase. Often infants will be disturbed or upset by the spasms. 
Spasms usually occur in clusters; this was observed by West in his original description. Approximately 
80% of spasms occur in clusters and 88% of patients report clustering phenomenon. Studies have 
shown that there is little diurnal variation in frequency of spasm/cluster over a 24 hour period. 
However, spasms do not occur in sleep but occur most frequently on awakening or just before sleep. 
Electroencephalographic findings 
The classic hypsarrhythmia seen in patients with IS is an EEG pattern of a poorly organized, high 
amplitude (500– 1000 𝜇V), slow background, with accompanying multifocal epileptiform discharges, 
seen interictally, with generalized electrodecrement seen ictally during the spasms.  It is however not 
present in all cases of IS and variation or modification of hypsarrhythmia is reported. . For an 
excellent review of the pattern and implication of these variants of hypsarrythmia readers are referred 
to Hrachovy and Frost. (Hrachovy and Frost, 2003)  
There are children with IS whose inter-ictal EEG does not show hypsarrythmia or any of its variants. 
Caraballo et al followed up 16 such cases and observed focal spikes in seven cases, bilateral spikes 
and spike and waves in five patients, multifocal spikes in two and normal inter-ictal EEG in tow 
patients.(Caraballo et al., 2011) 
Benign non-epileptic IS has been reported by some workers and these children have an excellent 
prognosis with a normal EEG. According to current knowledge a normal EEG excludes the diagnosis 
of IS.(Dravet et al., 1986) 
Management 
With regards to interventions, the first report of corticoadrenal hormones used therapeutically in 
epilepsy was published by McQuarrieet al.(McQuarrie et al., 1942)McQuarrie observed (1931) 
seizures induced in epileptic patients by increasing water intake and giving ADH. Deoxycortisone was 
proposed to cause opposite effects and therefore could have antiepileptic properties. They 
administered the intervention to one patient, with complete resolution of seizures. Further studies 
specific to the role of corticosteroids in the treatment of ES, added to the wealth of data relating to this 
condition and the combined findings led to recommendations from the American Academy of 
Neurology, as well as the Cochrane database, for hormonal therapies to be the optimal 
intervention.(Go et al., 2012; Hancock et al., 2013) 
Data from The National Infantile Spasms Consortium of North America supported the need to follow 
accepted standardized protocols namely adrenocorticotrophic hormone (ACTH), oral corticosteroids 
or vigabatrin (VBG).(Knupp et al., 2016) The paper stated that more favourable responses occurred in 
the ACTH treated group but this was a prospective case series and not a scientific clinical trial and 
therefore the results need to be viewed with some caution because of the possibility of bias .  
The role of vigabatrin was reported in a study in which 192 out of 250 infants with classic ES were 
retrospectively reviewed.(Aicardi et al., 1996) Median follow-up time was 7.6months (range 0.5-
28.6months). Initial suppression of ES occurred in 131 (68%) infants. In the group with TSC this was 
27/28 (96%).In infants under 3 months of age at the time of the spasms onset resolution occurred in 
18/20 (90%). Response time was 4 days and mean dose was 99mg/kg/day. Comparison of vigabatrin 
versus hydrocortisone in a prospective randomised multicentre study compared responses in 22 
patients with TSC.(Chiron et al., 1997) The study supported the superior efficacy and tolerability of 
VGB in infants with TSC and ES when compared with hydrocortisone. However, it should be noted 
that hydrocortisone is rarely used elsewhere in the treatment of IS. Another study of 42 patients found 
no significant difference between vigabatrin and ACTH. In the VGB group 11/23 became spasm free 
with more efficacy seen for the patients with TSC and or malformations, with 13% reporting side 
effects.(Vigevano and Cilio, 1997) 14/19 administered ACTH responded with earlier resolution on 
EEG and side effects reported by 37%. 
Concern relating to VGB and visua lfield defects has affected confidence in prescribing the 
product.(Vanhatalo et al., 2002) A study of 91 children aged between 5.6 and 17.9 years, found visual 
field constriction in 17/91 (which was not statistically significant). But significant correlation was found 
with development of constriction in children who were treated for longer periods. The constricted 
group were treated for 46.1 months compared to the normal visual field (VF) group who were treated 
for 33.5 months. Also the cumulative dose was a statisically significant positive risk indicator. 
The multicentre, randomised controlled trial, the United Kingdom Infantile Spasms Study (UKISS) 
compared prednisolone or tetracosactide versus VGB in the treatment of IS.(Lux et al., 2004) In this  
study children with TSC were excluded. The primary clinical outcome was the proportion with no 
spasms at days 13 and 14. This was found in 73% of the hormonal group and 54% of the VGB group 
which was statistically significant. Adverse events were reported in 55% of the hormonal group and 
54% of the VGB group. Follow up data at 14 months based on the absence of spasms at final clinical 
assessment found that this was the case for 41/55 of the hormonal group (75%) compared to 39/51 of 
the VGB group (76%).(Lux et al., 2005) The mean VABS score for the hormone group was 78·6 [SD 
16·8] and the VGB group was 77·5 [SD 12·7]; also not significant. However, there was a significant 
aetiology-treatment interaction with respect to developmental outcome with hormonal therapies being 
associated with a significantly better developmental outcome than vigabatrin in those children with no 
proven aetiology for their spasms.  
In resource limited settings access to ACTH or vigabatrin may not be viable. Indeed even in many 
parts of the US the cost of ACTH often precludes its use as therapy. Data is evolving supportive of 
high dose prednisolone (8mg/kg/day, or 40- 60mg per day, for 2 weeks of therapy followed by a 2 
week taper) with equivalent responses to those seen with ACTH.(Kossoff et al., 2009; Hussain et al., 
2014) 
The ketogenic diet has been proposed as an alternate intervention for infants with epileptic spasms 
but studies have provided inconsistent results.(Eun et al., 2006; Hong et al., 2010; Kang et al., 2011; 
Kayyali et al., 2014; Kossoff et al., 2008; Lee et al., 2013; Pires et al., 2013; Hussain et al., 2016) 
Most studies introduce the intervention after failure of standard therapy. The ideal study is yet to be 
performed to clarify if the KD is a viable option in the management of ES. 
Precision medicine is a concept which, whilst relatively novel, may have a role for isolated patients 
with IS. An example could be in the setting of patients with IS related to KCNT1 mutations.(Ohba et 
al., 2015) Effective response to quinidine is reported in one case study.(Fukuoka et al., 2016) Some 
caution is needed however as there is variable response for patients with KCNT1 mutations and early 
onset epileptic encephalopathies.(Chong et al., 2016)   
Outcome 
Focusing on the developmental outcome, no difference in developmental outcome was found 
between the two treatment groups (hormonal treatment versus VBG) for all infants.(Darke et al., 
2010) In the subgroup of infants with no identified aetiology, hormonal treatments had a significantly 
higher composite VABS scores than those allocated vigabatrin when measured both at 14 months 
and at 4 years. 
The study was extended into The International Collaborative Infantile Spasms Study (ICISS), which 
measured cessation of spasms (Day 14 – 42), cessation of spasms and resolution of hypsarrhythmia 
(electro-clinical outcome), development at 18 months and 3.5 years. The primary clinical outcome of 
cessation of seizures between Day 14 and 42 was seen in 108 (56.6%) out of 191 allocated hormonal 
treatment compared to 133 (71.9%) out of 185 allocated combination therapy (VGB and hormonal 
therapy).  Difference in response was 15.3% (95% CI = 5.4% to 25.2%) chi2 = 9.6, p = 0.002.   The 
median response time in responders for those on combination therapy was 2 days (IQR 2-4) 
compared to a median response time of 4 days (IQR 3-6) for those responding to hormonal therapy 
alone (Wilcoxon ranksum z=6.04 p < 0.0001). The implication being that optimal management would 
be through combination of hormonal as well as VBG treatment.  
Another key factor associated with developmental outcome is the “lead time to treatment” i.e.the time 
from seizure onset to initiation of treatment.(O'Callaghan et al., 2011) In this study that looked at 
participants in UKISS (ref Lux et al.) lead-time to treatment was categorised as 7 days or less, 8 to 14 
days, 15 days to 1 month, 1 to 2 months and greater than two months. The study showed that the 
earlier the intervention the better, each increase in category of lead time duration was associated with 
a 3.9 (95% CI 0.4 to 7.3, p = 0.014) decrease in VABS score.  
Additional influences on outcome relate to the impact of the underlying aetiology. In general 
symptomatic cases do worse than infants with cryptogenic causes.(Riikonen, 2001) Further, certain 
genetic mutations can have specific outcomes, such as ARX mutations which impact on autistic 
outcome.(Turner et al., 2002) The prompt response to treatment and a short  duration of 
hypsarrythmia is also an indicator.(Rener-Primec et al., 2006) This has also been reported in patients 
with infantile spasms and TSC (Jambaqué et al., 2000) as well as those with IS and Trisomy 21 
(Eisermann et al., 2003).  
Epilepsy surgery 
There is a subset of children with ES who may be suitable for epilepsy surgery. Focal lesions in 
Infantile Spasms are supported by findings in EEG recordings in 110/149 in one study (Riikonen, 
1982) and in 28/67 in another,(Kramer et al., 1997). Also on neuroimaging (CT/MRI) in 17/37 
infants,(Shields et al., 1992) and following positron emission tomography (PET) in 5/13 infants 
(Chugani et al., 1993) and 30/97 infants(Chugani and Conti, 1996). Epilepsy surgery was undertaken 
in 23 children between 1-10months of age (mean 9.5months), based on supporting data from PET 
and EEG which was lateralised/localised in all.(Chugani et al., 1993) Fifteen children underwent 
cortical resection and 8 hemispherectomy. At follow-up between 4-67months, 15 were seizure free, 4 
had between 75-90% seizure freedom and 4 continued to have seizures.  
With regards to developmental outcome, a study of 24 children with IS (15 girls) who underwent 
epilepsy surgery found a significant increase in developmental level at 2 years postsurgery compared 
with presurgical levels.(Asarnow et al., 1997) Younger age at operation correlates with a better 
outcome.(Riikonen, 1982; Koo et al., 1993; Favatà et al., 1987; Glaze et al., 1988) The longer the 
period of seizure duration before surgical intervention the lower Vineland DQ. (Jonas et al., 2005) 
This is further supported by the study by Loddenkemper et al which found that better developmental 
outcome was found in the early surgical intervention group. (Loddenkemper et al., 2007) 
Summary / Overall  
Epileptic spasms remain in many ways a connundrum, the ideal intervention is still unravelling, as well 
as how to best to screen patients with the intent for optimal care, and certainly with regards to the 
genetic causative mutations, the list could be exhaustive. As the vast range of genetics causes for ES 
evolve, it will be important to structure cost effective screening tools and to assess where the results 
will alter management i.e. precision medicine. However in most settings early recognition and 
intervention remain the priority of care to aim for optimal outcome for the infant.   
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